MAPS has announced that a blinded administrative interim analysis has confirmed no changes to the planned sample size are necessary to provide sufficient statistical power to detect the efficacy of MDMA-assisted therapy for PTSD in the second of two Phase III trials. Per their agreement with the FDA, the Phase III trial was designed to enrol at least 100 participants in order to confirm the efficacy and further investigate the safety of the treatment.
Category Press Release
Published in Cision
Companies Featured
MAPSMAPS stands for Multidisciplinary Association for Psychedelic Studies, it's the front runner in making psychedelics a legal way to use (and improve) in therapy.